Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the appointment of Dr. Yael Margolin as an independent member of the Company’s Board of Directors.
- Dr. Yael Margolin has more than 35 years of experience as senior manager, chief executive officer and board member in venture capital and in the pharmaceutical and biotech industries, leading strategic and business planning, financing, team building, product development and corporate partnerships.
- Dr. Margolin is a founder of mentoring@8400, a boutique voluntary mentoring program for young CEOs in Israel.
- Dr. Margolin commented, “Purple’s pipeline of oncologic drugs that focus on harnessing the tumor microenvironment have strong potential.
- I’m pleased to join this excellent group of executives, researchers, and board members to help advance much needed treatments for patients in need.”
“We are pleased and honored to have Dr. Margolin join our board.